Down 30.7% on Oct 27, and still 31% under its Oct 26 close.
“Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK®.”
−3Insider trades
ARTV's Quality Score fell 1 point on Wed, Nov 4, to -10. Its daily range widened again.
Follow ARTV's trial news. Pro members can get an alert when Artiva Biotherapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Since its Oct 2024 high | Down 73% |
| Latest filing | 8-K, Oct 27 |
Artiva halts AlloNK development, cuts 94% of workforce
A results day: the move is left out.
After its last 4 reports it closed -7.3% on average, higher 1 of 4 times.
The company says its cash lasts into 2029 (8-K, Aug 6).
An officer, Christopher Horan, sold 10,423 shares on Nov 2. 30 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
ARTV is #283 of 291 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 283 |
Expected to report Thu Nov 12, after the close (in 8 days). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Oct 27, 2026 | -31.0% | -30.7% | -32.0% |
| Aug 6, 2026 | +0.4% | -2.7% | -2.4% |
| May 8, 2026 | -3.8% | -13.0% | -14.7% |
Sales fell every year from 2023 to 2025, to $0. It lost money in each of the three years.
2 insiders bought $109M across 21 filings, and 5 insiders sold $2.3M across 17 filings, in the last 6 months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: ARTV is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
ARTV scores -10 today, which Breakaway calls Poor. It is #283 of 291 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 30.7% on Oct 27, and still 31% under its Oct 26 close. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
ARTV scores -10 today, which Breakaway calls Poor (below zero). That is #283 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ARTV's -10.
2 insiders bought $109M across 21 filings, and 5 insiders sold $2.3M across 17 filings, in the last 6 months. The newest is Fred Aslan, Chief Executive Officer, who sold $260K on Nov 2. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.